478 related articles for article (PubMed ID: 35831153)
21. Design of the randomized, placebo-controlled evolocumab for early reduction of LDL-cholesterol levels in patients with acute coronary syndromes (EVOPACS) trial.
Koskinas KC; Windecker S; Buhayer A; Gencer B; Pedrazzini G; Mueller C; Cook S; Muller O; Matter CM; Räber L; Heg D; Mach F;
Clin Cardiol; 2018 Dec; 41(12):1513-1520. PubMed ID: 30421481
[TBL] [Abstract][Full Text] [Related]
22. In-hospital initiation of PCSK9 inhibitor and short-term lipid control in patients with acute myocardial infarction.
Lou B; Liu H; Luo Y; Jiang GT; Wu H; Wang C; Wu Y; Zhou B; Yuan Z; She J; Liu J
Lipids Health Dis; 2022 Oct; 21(1):105. PubMed ID: 36280861
[TBL] [Abstract][Full Text] [Related]
23. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
Sahebkar A; Watts GF
Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
[TBL] [Abstract][Full Text] [Related]
24. Three Musketeers for Lowering Cholesterol: Statins, Ezetimibe and Evolocumab.
Xu Q; Deng Y; Xiao J; Liu X; Zhou M; Ren Z; Peng J; Tang Y; Jiang Z; Tang Z; Liu L
Curr Med Chem; 2021; 28(5):1025-1041. PubMed ID: 32368969
[TBL] [Abstract][Full Text] [Related]
25. Effect of Evolocumab in Patients With Prior Percutaneous Coronary Intervention.
Furtado RHM; Fagundes AA; Oyama K; Zelniker TA; Tang M; Kuder JF; Murphy SA; Hamer A; Wang H; Keech AC; Giugliano RP; Sabatine MS; Bergmark BA
Circ Cardiovasc Interv; 2022 Mar; 15(3):e011382. PubMed ID: 35209731
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia.
Rosenson RS; Jacobson TA; Preiss D; Djedjos CS; Dent R; Bridges I; Miller M
Cardiovasc Drugs Ther; 2016 Jun; 30(3):305-13. PubMed ID: 27240673
[TBL] [Abstract][Full Text] [Related]
27. Proprotein convertase subtilisin/kexin type 9 inhibition after acute coronary syndrome or prior myocardial infarction.
Schwartz GG; Giugliano RP
Curr Opin Lipidol; 2022 Jun; 33(3):147-159. PubMed ID: 35695614
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial.
Nissen SE; Stroes E; Dent-Acosta RE; Rosenson RS; Lehman SJ; Sattar N; Preiss D; Bruckert E; Ceška R; Lepor N; Ballantyne CM; Gouni-Berthold I; Elliott M; Brennan DM; Wasserman SM; Somaratne R; Scott R; Stein EA;
JAMA; 2016 Apr; 315(15):1580-90. PubMed ID: 27039291
[TBL] [Abstract][Full Text] [Related]
29. Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial.
Giugliano RP; Keech A; Murphy SA; Huber K; Tokgozoglu SL; Lewis BS; Ferreira J; Pineda AL; Somaratne R; Sever PS; Pedersen TR; Sabatine MS
JAMA Cardiol; 2017 Dec; 2(12):1385-1391. PubMed ID: 29117276
[TBL] [Abstract][Full Text] [Related]
30. Anti-PCSK9 antibodies for hypercholesterolaemia: Overview of clinical data and implications for primary care.
Descamps OS; Fraass U; Dent R; März W; Gouni-Berthold I
Int J Clin Pract; 2017 Aug; 71(8):. PubMed ID: 28750477
[TBL] [Abstract][Full Text] [Related]
31. Long-term Low-Density Lipoprotein Cholesterol-Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia: Results Up to 4 Years From the Open-Label OSLER-1 Extension Study.
Koren MJ; Sabatine MS; Giugliano RP; Langslet G; Wiviott SD; Kassahun H; Ruzza A; Ma Y; Somaratne R; Raal FJ
JAMA Cardiol; 2017 Jun; 2(6):598-607. PubMed ID: 28291870
[TBL] [Abstract][Full Text] [Related]
32. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial.
Schwartz GG; Bessac L; Berdan LG; Bhatt DL; Bittner V; Diaz R; Goodman SG; Hanotin C; Harrington RA; Jukema JW; Mahaffey KW; Moryusef A; Pordy R; Roe MT; Rorick T; Sasiela WJ; Shirodaria C; Szarek M; Tamby JF; Tricoci P; White H; Zeiher A; Steg PG
Am Heart J; 2014 Nov; 168(5):682-9. PubMed ID: 25440796
[TBL] [Abstract][Full Text] [Related]
33. [The importance of intensive lipid-lowering therapy after acute coronary syndrome: changing the paradigm to improve the achievement of targets].
Muccioli S; Giglio C; Annibali G; Cerutti E; Civera S; Casati R; Delnevo F; De Rosa C; Bongioanni S; Colopi M; Gandolfo N; Aranzulla T; Bianchi F; Blandino A; Borrione M; Grossi S; Luceri S; Mabritto B; Carceri C; Meliga E; Parrini I; Pizzuti A; Scrocca I; Sibona Masi A; Tomasello A; Gasco A; Musumeci G
G Ital Cardiol (Rome); 2022 Jul; 23(7):553-561. PubMed ID: 35771021
[TBL] [Abstract][Full Text] [Related]
34. Position of the Polish Cardiac Society on therapeutic targets for LDL cholesterol concentrations in secondary prevention of myocardial infarctions.
Mitkowski P; Witkowski A; Stępińska J; Banach M; Jankowski P; Gąsior M; Wita K; Bartuś S; Burchardt P; Farkowski MM; Gierlotka M; Gil R; Leszek P; Sterliński M; Szymański P; Tajstra M; Tycińska A; Wojakowski W
Kardiol Pol; 2023; 81(7-8):818-823. PubMed ID: 37489830
[TBL] [Abstract][Full Text] [Related]
35. Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk).
Bonaca MP; Nault P; Giugliano RP; Keech AC; Pineda AL; Kanevsky E; Kuder J; Murphy SA; Jukema JW; Lewis BS; Tokgozoglu L; Somaratne R; Sever PS; Pedersen TR; Sabatine MS
Circulation; 2018 Jan; 137(4):338-350. PubMed ID: 29133605
[TBL] [Abstract][Full Text] [Related]
36. Low-Density Lipoprotein Cholesterol After an Acute Coronary Syndrome: How Low to Go?
Qamar A; Libby P
Curr Cardiol Rep; 2019 Jun; 21(8):77. PubMed ID: 31250329
[TBL] [Abstract][Full Text] [Related]
37. Lipid management in ACS: Should we go lower faster?
Gencer B; Mach F
Atherosclerosis; 2018 Aug; 275():368-375. PubMed ID: 30015301
[TBL] [Abstract][Full Text] [Related]
38. Recent Updates on the Use of PCSK9 Inhibitors in Patients with Atherosclerotic Cardiovascular Disease.
Dixon DL; Pamulapati LG; Bucheit JD; Sisson EM; Smith SR; Kim CJ; Wohlford GF; Pozen J
Curr Atheroscler Rep; 2019 Mar; 21(5):16. PubMed ID: 30877491
[TBL] [Abstract][Full Text] [Related]
39. Safety and Efficacy of Perioperative Use of Evolocumab in Myocardial Infarction Patients: Study Protocol for a Multicentre Randomized Controlled Trial.
Luan Y; Wang M; Zhao L; Xu T; Fu G; Zhang W
Adv Ther; 2021 Apr; 38(4):1801-1810. PubMed ID: 33638801
[TBL] [Abstract][Full Text] [Related]
40. Effect of PCSK9 inhibitor on lipoprotein particles in patients with acute coronary syndromes.
Li T; Zhang Y; Cong H
BMC Cardiovasc Disord; 2021 Jan; 21(1):19. PubMed ID: 33413096
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
